PhytoHealth (TPE:4108) Other Financing: NT$0.0 Mil (TTM As of Dec. 2025)


TPE:4108 PhytoHealth Corp TPE:4108
72 GF Score
Price NT$12.00
GF Value NT$15.95
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is PhytoHealth Other Financing?

PhytoHealth TPE:4108 72 Other Financing is NT$0.0 Mil as of Dec. 2025. GuruFocus rates TPE:4108 with a GF Score™ of 72/100 and a GF Value™ of NT$15.95 (Modestly Undervalued). The stock has 2 warning signs investors should review.

PhytoHealth's Other Financing for the three months ended in Dec. 2025 was NT$0.0 Mil.

PhytoHealth's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.0 Mil.

PhytoHealth Other Financing Historical Data

* Premium members only.

The historical data trend for PhytoHealth's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhytoHealth Other Financing Chart

PhytoHealth Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.12 0.01 0.00 156.01 0.03

PhytoHealth Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.03 0.00 0.00
TPE:4108
72GF Score
PhytoHealth Corp TPE:4108
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PhytoHealth Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of NT$0.0 Mil mean?
PhytoHealth (TPE:4108) has a Other Financing of NT$0.0 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for PhytoHealth and its competitors.
Is PhytoHealth's Other Financing too high?
PhytoHealth's current Other Financing is NT$0.0 Mil. Overall, PhytoHealth has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhytoHealth's Other Financing compare to ZTS and UTHR?
PhytoHealth's Other Financing of NT$0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for PhytoHealth and its competitors. PhytoHealth's current Other Financing is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhytoHealth stock overvalued right now?
Based on GuruFocus' analysis, PhytoHealth (TPE:4108) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$15.95, compared to a current price of NT$12.00 — trading 24.8% below its estimated fair value. The current Other Financing is NT$0.0 Mil. PhytoHealth's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For PhytoHealth (TPE:4108), the current Other Financing is NT$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PhytoHealth (TPE:4108) Overvalued in 2026?

Based on GuruFocus' analysis, PhytoHealth stock appears to be undervalued. The current stock price of NT$12.00 is trading 24.8% below its estimated GF Value™ of NT$15.95. GuruFocus considers PhytoHealth to be Modestly Undervalued.

Key valuation signals for TPE:4108:

  • Other Financing: NT$0.0 Mil
  • GF Value™: NT$15.95 vs. price of NT$12.00 (24.8% below fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the TPE:4108 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PhytoHealth Business Description

Address Fuxing North Road, No. 167, 5th Floor - 1, Zhongshan District, Taipei, TWN, 104
PhytoHealth Corp engages in the research and development, production, manufacture, and sale of pharmaceutical drugs, cosmetics, Class B drugs, and dietary supplements. The company's product portfolio comprises White Blood Crystals Injection, White Pain Relief Soft Capsules, WhiteGilead, and White AminoSpeed supplements. Additionally, it is developing PHN031 (White Bone) for the prevention of osteoporosis; PHN033 (White Sugar) for the treatment of diabetic nephropathy; PHN016 for cancer treatment; and PHN017 for the treatment of cytokine storm. The company's reportable operating segments are: Pharmaceutical drugs and dietary supplement, which generate maximum revenue, Medical diagnostic products, and Precision medical equipment. Geographically, it derives maximum revenue from Taiwan.
72GF Score

Get the complete analysis for TPE:4108

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$12.00
Price
NT$15.95
GF Value